NCT00545363View on ClinicalTrials.gov

A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)

PHASE4CompletedINTERVENTIONAL
Enrollment

716

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Ibandronate

Participants will receive ibandronate 150 mg QM orally for 6 months.

Trial Locations (52)

1004

Riga

1027

Budapest

1032

Budapest

1038

Riga

1113

Budapest

1525

Ljubljana

3400

Liepāja

3529

Miskolc

4043

Debrecen

5600

Békéscsaba

6720

Szeged

7624

Pécs

8000

Székesfehérvár

9700

Szombathely

101990

Moscow

111123

Moscow

115552

Moscow

117036

Moscow

117997

Moscow

125315

Moscow

127299

Moscow

127473

Moscow

129110

Moscow

150003

Yaroslavl

190068

Saint Petersburg

199034

Saint Petersburg

300736

Timișoara

300941

Craiova

394066

Voronezh

400006

Cluj-Napoca

620102

Yekaterinburg

664047

Irkutsk

900709

Constanța

LV-1012

Riga

44-100

Gliwice

30-510

Krakow

90-549

Lodz

60-355

Poznan

00-719

Warsaw

00-909

Warsaw

02-507

Warsaw

02-637

Warsaw

50-367

Wroclaw

011172

Bucharest

011364

Bucharest

011461

Bucharest

011863

Bucharest

975 17

Banská Bystrica

826 06

Bratislava

034 91

Ľubochňa

921 12

Piešťany

080 01

Prešov

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00545363 - A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) | Biotech Hunter | Biotech Hunter